On August 20, 2026, Jiazi Guangnian hosted the "Rapids – 2026 Jiazi Gravity X · Technology Industry Investment Conference," where the "2025-2026 China Technology Industry Investment Rankings" were officially released. Efung Capital was honored with the title of 2025-2026 Top 30 Best Healthcare Investment Institutions.

In 2026, China's technology investment landscape is navigating new "rapids."

Artificial intelligence is accelerating the reshaping of the industrial landscape, with hard tech remaining a core focus of capital. At the same time, valuation systems, exit pathways, and models of industrial collaboration are undergoing profound changes. In the face of faster technological iteration and an increasingly complex market environment, the key to investment is no longer merely chasing trends—it lies in navigating cycles and identifying truly innovative forces with strong technological moats, commercial potential, and long-term value.

This year's rankings feature two major categories—Investment Institutions & Investors, and Most Valuable Investee Companies—covering 9 main lists and 28 sub-lists. The focus spans key technology sectors including artificial intelligence, embodied intelligence, semiconductors and integrated circuits, smart manufacturing, healthcare, commercial aerospace, new energy, and advanced materials. The rankings seek to honor and pay tribute to investment institutions, investors, and tech enterprises that maintain professional judgment and uphold long-termism amid the rapids.

As the rapids surge forward, value becomes ever more evident. Looking ahead, Efung Capital will continue to deepen its roots in the healthcare innovation ecosystem, leveraging professional due diligence and industrial ecosystem empowerment to accompany truly innovative enterprises—those with clinical value and global competitiveness—through market cycles toward growth and maturity. Together with all fellow travelers, we remain committed to anchoring value amid uncertainty and co-creating the future through transformation.

Disclaimer

This content represents the views of the Company based solely on currently available public information and materials provided by portfolio companies. It does not constitute investment advice, medical advice, or a guarantee of any specific enterprise's performance. Investment involves risk; please exercise caution when entering the market. Readers are advised to make independent judgments based on publicly disclosed information. Unauthorized reproduction or commercial use is prohibited.